New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 9, 2014
06:19 EDTAGN, VRXAllergan plans broad restructuring plan, Bloomberg says
Allergan (AGN), the pharmaceutical maker that is being chased by Valeant (VRX) and Bill Ackmanís hedge fund, will shelve unpromising pipeline medicines and revamp management incentives, according to Bloomberg, citing two people with knowledge of the matter. The sources said that the restructuring plan, which is set to be explained during Allergan's upcoming earnings announcement, will also detail companywide cost reductions including some legacy expenses. Reference Link
News For AGN;VRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
March 16, 2015
10:18 EDTVRXValeant should win Salix with increased offer, says Cantor
Subscribe for More Information
10:14 EDTAGNOptions with decreasing implied volatility
Options with decreasing implied volatility: EXPR ULTA SGMS QIHU BKS PAY URBN AGN AGNC
09:22 EDTVRXOn The Fly: Pre-market Movers
Subscribe for More Information
08:17 EDTVRXValeant rises 1% after sweetening Salix takeover offer
Subscribe for More Information
08:06 EDTVRXValeant ses Salix deal closing on April 1
08:05 EDTVRXValeant raises offer price for Salix to $173 per share from $158
Subscribe for More Information
08:04 EDTVRXValeant, Salix agree on amended terms to merger agreement
Subscribe for More Information
07:50 EDTVRXValeant to raise offer for Salix to $173 per share, DJ reports
Dow Jones cites sources.
March 13, 2015
15:50 EDTVRXValeant announces HSR clearance for acquisition of Salix
Valeant Pharmaceuticals (VRX) announced that it has received early termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 with respect to its proposed acquisition of Salix Pharmaceuticals (SLXP). The expiration of the waiting period satisfies one of the conditions to consummate the tender offer and Valeant expects to be in the position to close the transaction on April 1.
13:46 EDTVRXValeant to raise Salix bid above $160 per share after Endo entry, NYT says
In response to Endo (ENDP) making a rival bid for Salix (SLXP), Valeant Pharmaceuticals (VRX) now plans to team up with Bill Ackman's Pershing Square and other top shareholders to raises its bid for Salix to above $160 per share, all in cash, according to The New York Times, citing people briefed on the matter. The exact price of Valeantís raised offer was not yet known, the report stated. Salix shares are down about 1% to $168.88 in afternoon trading. Reference Link
13:43 EDTVRXValeant seen hiking Salix bid above $160 per share cash, NYT says
Subscribe for More Information
08:15 EDTVRXAckman says shares of Valeant 'very cheap'
Subscribe for More Information
08:14 EDTVRXAckman says does not view Endo bid for Salix as credible
Subscribe for More Information
08:13 EDTVRXAckman says Endo would be very highly levered with Salix deal
Bill Ackman of Pershing Square is speaking on CNBC.
08:11 EDTVRXAckman says Valeant CEO will not overpay for Salix
Bill Ackman of Pershing Square is speaking on CNBC.
March 12, 2015
11:29 EDTVRXEndo repeats FY15 adjusted EPS view $4.35-$4.55, consensus $4.48
Subscribe for More Information
11:12 EDTVRXOptions with increasing implied volatility
Subscribe for More Information
08:11 EDTVRXEndo offer for Salix unlikely to trump Valeant, says Leerink
Leerink believes Endo (ENDP) is unlikely to win the acquisition of Salix (SLXP) since Valeant's (VRX) offer is in all cash and Endo's shares sold off on the news, lessening the value of its buyout proposal. The firm says the estimated deal accretion of 15%-20% may not be enough to push up Endo's stock price.
07:57 EDTVRXValeant bid for Salix superior to Endo offer, says Canaccord
Subscribe for More Information
05:55 EDTVRXStocks with implied volatility movement; TEVA VRX
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use